← Back to Search

Ablation Catheter

Treatment Group for Ventricular Tachycardia

N/A
Recruiting
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to confirm the safety and effectiveness of the FlexAbility SE catheter for treating ventricular tachycardia. The device works by creating small scars in the heart to block abnormal electrical signals, helping to restore a normal heart rhythm. The study focuses on patients with this serious heart condition who may not respond well to other treatments. Catheter ablation has emerged as an important and effective treatment option for many recurrent ventricular arrhythmias.

Eligible Conditions
  • Ventricular Tachycardia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment GroupExperimental Treatment1 Intervention
Single Arm Group to receive ablation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FlexAbility SE Ablation Catheter
2018
N/A
~600

Find a Location

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
652 Previous Clinical Trials
416,687 Total Patients Enrolled
Kristin Ruffner, PhDStudy DirectorClinical Program Director
9 Previous Clinical Trials
10,840 Total Patients Enrolled
~100 spots leftby Aug 2028